Mon, Jan 26, 2015, 4:08 AM EST - U.S. Markets open in 5 hrs 22 mins

Recent

% | $
Quotes you view appear here for quick access.

Cubist Pharmaceuticals Inc. Message Board

  • i.alaric i.alaric Apr 4, 2013 9:34 PM Flag

    War Against Superbugs Likely Unwinnable: Doctors

    Google the subject of this post. The article is not a cheery one but the message is clear. The need for these kinds of drugs is going to continue to explode. CBST is the leader in this field. Of course they`re not even mentioned in the article.. cause the crooks on wall street want shares on sale. Same reason Cantor Fitzgerald downgraded cbst yesterday. What a circus. Doesn't mean us little guys can't accumulate too though!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • some governments also have incentives to let endemics occur for population control, decrease social program burden, encourage positve gene expression

      Sentiment: Hold

      • 1 Reply to kreactor
      • from a purely machiavellian and long-term view... these incentives make sense. With a totalitarian state it could happen. In the west I don't see it playing out though. The west needs to get healthcare costs under control. superbugs are a drain on the health care system. Prevention is key, such as proper sterilization procedures at hospitals. But prevention also means agressively treating existing cases so there is less time for contagion. Want to see clear evidence the government is taking this threat seriously? drum roll please.... The FDA's recent QIDP grant for ceftolozane/tazobactam in HABP/VABP and cUTI, as well as FDA's Fast track status provided for ceftolozane/tazobactam (CXA-201) in cIAI and for surotomycin (CB-315) in CDAD.

 
CBST
101.940.00(0.00%)Jan 21 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.